[Prostaplant treatment of benign prostatic hyperplasia]

80 patients aged 48 to 91 years with verified benign prostatic hyperplasia (BPH) stage I and II, having contraindications to surgery, received prostaplant, extract of Sabal serrulata palm fluit, in a dose 320 mg once a day. The treatment resulted in improvement of subjective and objective parameters (the total IPSS score improved by 32.3%, quality of life by 36.4%; maximal urine flow rate by 27.4%, respectively). Residual urine volume reduced in patients of group I by 26.8%, in patients of group II by 25.5%. The drug tolerance was good. 3 patients failed treatment. Good and satisfactory effects were achieved in 69 and 8 patients, respectively. Therefore, prostaplant is effective in BPH.